Organic Chemicals
Featured Products
Factory Sells Best Quality Cyclopenthiazide 742-20-1 with steady supply
- Molecular Formula: C13H18ClN3O4S2
- Molecular Weight: 379.889
- Appearance/Colour: crystals
- Vapor Pressure: 1.29E-14mmHg at 25°C
- Melting Point: 238-242ºC
- Refractive Index: 1.6
- Boiling Point: 605.6 °C at 760 mmHg
- PKA: 9.00±0.40(Predicted)
- Flash Point: 320.1 °C
- PSA: 135.12000
- Density: 1.471 g/cm3
- LogP: 4.92630
Cyclopenthiazide(Cas 742-20-1) Usage
|
World Health Organization (WHO) |
Cyclopenthiazide, a thiazide diuretic, was introduced in 1968. It continues to be used mainly in combination drugs. |
|
Drug interactions |
Potentially hazardous interactions with other drugs Analgesics: increased risk of nephrotoxicity with NSAIDs; antagonism of diuretic effect. Anti-arrhythmics: hypokalaemia leads to increased cardiac toxicity; effects of lidocaine and mexiletine antagonised. Antibacterials: avoid administration with lymecycline. Antidepressants: increased risk of hypokalaemia with reboxetine; enhanced hypotensive effect with MAOIs; increased risk of postural hypotension with tricyclics. Antiepileptics: increased risk of hyponatraemia with carbamazepine. Antifungals: increased risk of hypokalaemia with amphotericin. Antihypertensives: enhanced hypotensive effect; increased risk of first dose hypotension with postsynaptic alpha-blockers like prazosin; hypokalaemia increases risk of ventricular arrhythmias with sotalol. Antipsychotics: hypokalaemia increases risk of ventricular arrhythmias with amisulpride; enhanced hypotensive effect with phenothiazines; hypokalaemia increases risk of ventricular arrhythmias with pimozide - avoid. Atomoxetine: hypokalaemia increases risk of ventricular arrhythmias. Cardiac glycosides: increased toxicity if hypokalaemia occurs. Ciclosporin: increased risk of nephrotoxicity and possibly hypomagnesaemia. Cytotoxics: increased risk of ventricular arrhythmias due to hypokalaemia with arsenic trioxide; increased risk of nephrotoxicity and ototoxicity with platinum compounds. Lithium: excretion reduced, increased toxicity |
|
Metabolism |
Cyclopenthiazide appears to be entirely excreted unchanged in the urine. |
InChI:InChI=1/C13H18ClN3O4S2/c14-9-6-10-12(7-11(9)22(15,18)19)23(20,21)17-13(16-10)5-8-3-1-2-4-8/h6-8,13,16-17H,1-5H2,(H2,15,18,19)
742-20-1 Process route
-
-
92017-67-9
6-chloro-3-cyclopentylmethyl-1,1-dioxo-1,2(4)-dihydro-1λ6 -benzo[1,2,4]thiadiazine-7-sulfonic acid amide
-
-
742-20-1,96783-05-0,96783-06-1
cyclopenthiazide
| Conditions | Yield |
|---|---|
|
With
sodium tetrahydroborate; aluminium trichloride;
In
tetrahydrofuran;
|
-
-
121-30-2
chloraminophenamide
-
-
5623-81-4
2-cyclopentylacetaldehyde
-
-
742-20-1,96783-05-0,96783-06-1
cyclopenthiazide
| Conditions | Yield |
|---|---|
|
With
hydrogenchloride;
In
ethanol;
for 12h;
Ambient temperature;
|
742-20-1 Upstream products
-
121-30-2
chloraminophenamide
-
5623-81-4
2-cyclopentylacetaldehyde
-
92017-67-9
6-chloro-3-cyclopentylmethyl-1,1-dioxo-1,2(4)-dihydro-1λ6 -benzo[1,2,4]thiadiazine-7-sulfonic acid amide